Global leukemic cell population

The global leukemic cell population refers to the total burden of malignant hematopoietic cells within an individual, characterized by clonal expansion and a failure to undergo normal maturation (National Cancer Institute, 2023). This population is not a single molecular entity but a heterogeneous collection of cells that drive the progression of various leukemias, such as Acute Myeloid Leukemia (AML) or Chronic Lymphocytic Leukemia (CLL) (NIH, 2024). Therapeutic intervention aims to reduce this population to undetectable levels, a state known as minimal residual disease (MRD) negativity (PubMed, 2022). Drugs interact with this population by targeting specific intracellular pathways (e.g., kinase inhibitors), inducing DNA damage (e.g., cytotoxic chemotherapy), or marking cells for destruction by the immune system (e.g., monoclonal antibodies). Because it encompasses an entire cell lineage rather than a specific protein, it is classified as a disease state or therapeutic objective rather than a discrete pharmacological target. Monitoring the size and genetic evolution of this population is critical for adjusting treatment strategies and predicting relapse (StatPearls, 2023).

Other names

Leukemic cell burdenMalignant hematopoietic cellsLeukemic blastsLeukemic clones

Drugs targeting the global leukemic cell population work through diverse mechanisms, including the inhibition of DNA synthesis (antimetabolites), induction of double-strand breaks (anthracyclines), inhibition of oncogenic signaling (tyrosine kinase inhibitors), and the activation of apoptotic pathways (BCL-2 inhibitors) (StatPearls, 2023).